Phuturdex › Diseases › Typhoid fever
Drugs in development · updated 13 November 2026
Typhoid fever: drugs in development
What it is
Typhoid or typhoid fever is a reportable, fecal-oral, potentially fatal infectious disease, caused by the bacteria Salmonella typhi and characterized by a non-focal fever.
Source: Orphanet, “Typhoid” (ORPHA:99745), www.orpha.net · licence CC BY 4.0 · Orphadata data of 23 June 2026.
As of 13 November 2026 there are 3 active clinical trials (recruiting or ongoing, phases I–III) on 3 drugs for typhoid fever. One is experimental, that is not yet approved in the United States.
In Phuturdex every drug has its map of sites in Europe, every trial and its alerts, and you get an email when something changes. Full access free until 31 March 2027, no card needed.
Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Prevenar 13 | II | 1 | NCT07286370 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| CiprofloxacinOtiprio®, Cetraxal® | II | 1 | NCT07908030 |
| AspirinAsprin, Vazalore® | Early I | 1 | NCT04083950 |
Sorted by most advanced phase and number of active trials.
All 3 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Broader categories
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 13 November 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D014435 “Typhoid Fever”. Prevalence: Orphanet.